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Aspirin blocks formation of metastatic
intravascular niches by inhibiting platelet-
derived COX-1/thromboxane A2
Serena Lucotti, … , Anne J. Ridley, Ruth J. Muschel
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Because metastasis is associated with the majority of cancer-related deaths, its prevention
is a clinical aspiration. Prostanoids are a large family of bioactive lipids derived from the
activity of cyclooxygenase-1 (COX-1) and COX-2. Aspirin impairs the biosynthesis of all
prostanoids through the irreversible inhibition of both COX isoforms. Long-term
administration of aspirin leads to reduced distant metastases in murine models and clinical
trials, but the COX isoform, downstream prostanoid, and cell compartment responsible for
this effect are yet to be determined. Here, we have shown that aspirin dramatically reduced
lung metastasis through inhibition of COX-1 while the cancer cells remained intravascular
and that inhibition of platelet COX-1 alone was sufficient to impair metastasis. Thromboxane
A2 (TXA2) was the prostanoid product of COX-1 responsible for this antimetastatic effect.
Inhibition of the COX-1/TXA2 pathway in platelets decreased aggregation of platelets on
tumor cells, endothelial activation, tumor cell adhesion to the endothelium, and recruitment
of metastasis-promoting monocytes/macrophages, and diminished the formation of a
premetastatic niche. Thus, platelet-derived TXA2 orchestrates the generation of a favorable
intravascular metastatic niche that promotes tumor cell seeding and identifies COX-1/TXA2
signaling as a target for the prevention of metastasis.
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The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1jci.org
Introduction
Prostanoids are a family of bioactive lipids comprising prostaglandins 
(e.g., PGD2, PGE2, PGF2a), thromboxane A2 (TXA2), and prostacyclin 
(PGI2). The rate-limiting step of prostanoid biosynthesis is catalyzed 
by cyclooxygenase (COX), an enzyme with 2 isoforms, COX-1 and 
COX-2. Both COX-1 and COX-2 have virtually identical enzymatic 
activity, mediating the conversion of arachidonic acid into PGG2 and 
then into PGH2, the common precursor of all prostanoids (1). However, 
the spectrum of prostanoids synthesized by each isoform differs in 
vivo as a result of distinct expression patterns and functional coupling 
to prostanoid synthases in different cell types (2). For example, COX-
2 is induced in endothelial cells and macrophages during inflamma-
tion and wound healing and couples with PGE2 synthase in those cells 
to produce proinflammatory PGE2 (2, 3). In contrast, COX-1 is con-
stitutively expressed. In platelets COX-1 couples with TXA2 synthase 
(TXAS) to generate prothrombotic TXA2 upon procoagulant stimuli 
(e.g., collagen, thrombin, and adenosine diphosphate [ADP]) (4–6). 
Because of the differential expression of prostanoid synthases and 
COX-1 and COX-2, the activity of the 2 isoforms is rarely redundant.
The importance of COX and prostanoid pathways in metastasis 
is apparent from reports showing that their inhibition greatly curtails 
metastasis. NSAIDs, including aspirin, that inhibit both COX-1 and 
COX-2 generally reduce metastasis in clinical studies and murine 
models (7–9). In some reports specific COX-2 inhibition blocks 
metastasis (10, 11), but not in others (12). Looking at the downstream 
prostanoids, inhibition of TXA2 or of PGE2 synthesis also reduces 
metastasis in animal models, while PGI2 has been reported to inhibit 
metastasis (11–18), with some exceptions (12, 19). These reports raise 
the question of whether some prostanoids might be suitable targets 
for metastasis prevention or therapy.
The possibility of using COX or prostanoid synthesis inhibi-
tion as a preventive strategy for metastasis has been highlighted by 
both clinical and experimental studies. Aspirin is given clinically 
in a variety of doses to reduce cardiovascular events or inflamma-
tion. Because of its unique combination of irreversible inhibition 
of COX enzymes and short circulating half-life, low-dose aspirin 
preferentially inhibits COX-1 in platelets, reducing the production 
of prothrombotic TXA2 and other prostanoids (20). Thus, low-dose 
aspirin is given for prophylaxis of myocardial infarction and stroke. 
Higher doses of aspirin inhibit both COX isoforms in other tissues 
(21). In particular, the reduction of COX-2–derived PGE2 exerts 
antiinflammatory effects. Case-control studies and meta-analysis 
of randomized controlled trials have shown that aspirin given for 
these unrelated purposes reduces metastatic cancer (22, 23). This 
effect was significant over a range of primary tumor types, with a 
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they are crucial and which prostanoids 
might be responsible for their effects.
Here we demonstrate using a variety 
of different models that specific inhibi-
tion of COX-1 in platelets is sufficient 
to inhibit metastasis to the same extent 
as aspirin whereas inhibition of COX-2 
does not reduce metastatic colonization. 
We further show that COX-1 blockade 
leading to inhibition of TXA2 synthesis 
in platelets is sufficient to inhibit metas-
tasis. Lastly we provide evidence that 
the antimetastatic effect of COX-1 inhi-
bition is generally limited to the early 
stages of metastasis and that inhibition 
of COX-1 or of TXA2 synthesis prevents 
the formation of an intravascular meta-
static and premetastatic niche.
Results
Reduction of metastasis by aspirin correlates with the inhibition of 
thrombosis. We treated mice with different doses of aspirin (ASA; 
low, medium, and high), which were based on the low, medium, 
and high doses used in humans according to a body surface area 
dose conversion method and on previous literature (8, 36–38). Inhi-
bition of COX-1 was evaluated using serum levels of TXB2, a stable 
metabolite of TXA2 generated by platelet COX-1 activity during 
clotting (ex vivo) (Figure 1A and ref. 39). Greater than 95% reduc-
tion in TXB2 ex vivo is thought to indicate physiological inhibition 
of COX-1 (40). The medium and high doses, but not the low dose, 
of aspirin reduced TXB2 by more than 95% (Figure 1B) and, accord-
ingly, reduced COX-1–dependent (arachidonic acid and U46619, a 
stable analog of TXA2) agonist-induced platelet aggregation (Fig-
ure 1, C and D). COX-1–independent (ADP) platelet aggregation 
was not affected (Figure 1, C and D). Importantly, low-dose aspirin 
did not reduce serum TXB2 more than 95% over 6 days after the 
treatment began, suggesting that the drug does not accumulate 
over time (Supplemental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/JCI121985DS1).
more prominent effect on adenocarcinomas (23). While aspirin 
also reduces metastasis in murine models (8, 11, 24, 25), it is not 
generally established whether the reduction of metastasis can be 
attributed to inhibition of COX-1 or COX-2.
During hematogenous metastasis, tumor cells have adapted 
to co-opt diverse cell types, including platelets, endothelial cells, 
and immune cells, to survive the hostile environment of the blood 
circulation (26). In particular, cancer cells engage platelets to form 
small aggregates or clots on their surface through expression of tis-
sue factor (TF) (27) or P-selectin ligands (28, 29). Platelet aggrega-
tion and activation itself supports tumor cell survival in the circu-
lation, either directly or through recruitment of myeloid cells, and 
can initiate cancer cell spreading on the surface of the blood vessel 
and transendothelial migration (27, 29–33). Different prostanoids 
are synthetized by a variety of cells in the vascular niche and are 
essential to maintain cardiovascular homeostasis, but the levels 
and source of prostanoids often change dramatically between 
physiological and pathological conditions (3, 34, 35). Thus, in 
addition to uncertainly as to which COX isoform is responsible 
for supporting metastasis, it is unclear in which cell compartment 
Figure 1. Medium-dose aspirin reduces 
COX-1–dependent platelet aggregation. (A) 
Diagram of COX-1 and COX-2 products. Serum 
TXB2 represents COX-1 activity in platelets. 
Plasma PGE2 represents COX-2 activity in 
monocytes. (B) TXB2 in serum from C57BL/6 
mice treated with vehicle or aspirin (ASA; 
low, medium, or high) for 2 days before blood 
sampling (n = 3). (C and D) Agonist-induced 
aggregation of CD61-stained platelets from 
mice treated with vehicle or aspirin for 2 days. 
Arachidonic acid, U46619, and ADP were the 
agonists (n = 7 for vehicle group, 4 for all other 
groups). (E and F) Experimental design (E) and 
ex vivo PGE2 levels (F) in plasma from mice in 
B (n = 4). Data are represented as mean + SD 
(B and F), mean ± range (C). One-way ANOVA 
with Tukey’s multiple-comparisons test. *0.01 
< P ≤ 0.05; **0.001 < P ≤ 0.01; ***P ≤ 0.001.
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Spontaneous metastasis was also inhib-
ited by aspirin. BALB/c mice with 4T1-GFP–
derived subcutaneous tumors received vehi-
cle or aspirin treatment (Figure 2E). Tumor 
growth was similar in both treatment groups, 
although aspirin treatment was associated 
with enhanced tumor regression (Supple-
mental Figure 4A). Aspirin decreased num-
bers of lung and liver metastases, of dissemi-
nated tumor cells in the lungs (Figure 2, F–I), 
and of circulating tumor cells (CTCs) (Sup-
plemental Figure 4B) and the invasive ability 
of those CTCs (Supplemental Figure 4, C–E).
These data confirmed the inhibitory 
effect of aspirin on metastasis at doses that 
inhibit COX-1 activity and thrombosis, sug-
gesting that aspirin affects metastasis estab-
lishment through an antithrombotic effect.
COX-1 inhibition is sufficient to reduce 
metastasis. Since aspirin inhibits both COX-1 and COX-2 at metas-
tasis-suppressive doses, we determined the effect on metastasis 
of selective inhibitors of COX-1 (SC-560) or COX-2 (NS-398). 
Isoform specificity was confirmed by reduction of serum TXB2 
for COX-1 (Figure 3A) and plasma PGE2 for COX-2 (Figure 3B and 
Supplemental Figure 2). COX-1 inhibition by SC-560 significant-
ly reduced the number of metastatic lung nodules from B16F10 
cells (Figure 3, C and D) compared to the medium and high doses 
of aspirin (Figure 2B). COX-2 inhibition by NS-398 did not reduce 
the numbers (Figure 3, C and D), making it unlikely that metastatic 
seeding requires PGE2. However, NS-398–treated mice had smaller 
metastatic colonies (Figure 3, E and F), compatible with the report-
ed involvement of COX-2 in tumor cell proliferation (15). Using 
other models, SC-560 also reduced experimental lung metastasis 
from MC-38-GFP, 4T1, and MDA-MB-231-CFP cells (Supplemen-
tal Figure 3) and spontaneous lung and liver metastasis, pulmonary 
dissemination (Figure 3, G–J), and CTCs and their invasiveness 
from 4T1-GFP tumor–bearing mice (Supplemental Figure 4, B–E).
Fewer experimental metastases were generated by B16F10 
cells in COX-1–/– (Ptgs1–/–, indicated here as COX-1–/–) mice than in 
wild-type (COX-1+/+) (Figure 4, A and B). As expected, COX-1–/– 
Since COX-2 is not significantly expressed in blood cells in the 
absence of inflammation, we assayed COX-2 inhibition using plasma 
PGE2 after COX-2 induction by LPS (Figure 1, A and E, and ref. 41). 
All doses of aspirin reduced plasma PGE2 levels, demonstrating inhi-
bition of COX-2 (Figure 1F). Systemic PGE2 metabolites (PGE2M) 
were also reduced (Supplemental Figure 2). The antiinflammatory 
effect of low-dose aspirin has been previously suggested (37, 42). 
Thus aspirin inhibited COX-2 at all doses but only inhibited COX-1 
with physiological significance at the medium and high doses. 
Hence, the medium dose is the minimum dose to achieve antithrom-
botic effects in our model, similar to low-dose aspirin in humans.
The effects of aspirin on experimental metastasis were 
assessed in mice treated with aspirin starting 2 days before the i.v. 
injection of syngeneic B16F10 melanoma tumor cells (Figure 2A). 
Aspirin at the medium and high doses reduced the number of met-
astatic lung nodules by more than 50% (Figure 2, B and C). The 
number of colonies inversely correlated with aspirin intake (Figure 
2D). Aspirin (medium dose) similarly reduced the number of meta-
static lung nodules from MC-38-GFP, 4T1, and MDA-MB-231-CFP 
cells (Supplemental Figure 3), indicating a widespread inhibitory 
effect of aspirin on metastasis.
Figure 2. Aspirin reduces experimental metasta-
sis. (A) Schematic representation of experimental 
metastasis assay. (B and C) B16F10 metastatic 
lung nodules in C57BL/6 mice treated with vehicle 
(n = 6) or aspirin (n = 5, 5, and 6). (D) Correlation 
plot of urinary concentration of salicyluric acid 
(SUA) versus the number of metastatic lung 
nodules of mice in B. (E) Schematic representa-
tion of spontaneous metastasis assay. Scale bar: 
10 μm. (F–I) Single disseminated tumor cells in 
the lungs (F) and metastatic nodules to lungs (F 
and G) or liver (H and I) of BALB/c mice bearing 
4T1-GFP tumors, treated with vehicle or aspirin (n 
= 8 and 5 in F, 4 and 3 in H). Data are represented 
as mean + SD. One-way ANOVA with Tukey’s mul-
tiple-comparisons test (B, F, and H); Spearman’s 
rank correlation (D). *0.01 < P ≤ 0.05; **0.001 < P 
≤ 0.01; ***P ≤ 0.001.
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was given from day –2 to day +1 (–2→+1) for the intravascular phase, 
from day +1 to day +4 (+1→+4) for the extravasation phase, or from 
day +4 to day +21 (+4→+21) for the extravascular phase (Figure 
5A). Aspirin and SC-560 given during the intravascular phase of 
metastasis resulted in reduced numbers of metastatic lung nodules 
similar to treatment throughout. In contrast, administration during 
the later extravasation and extravascular phases did not affect 
metastasis (Figure 5, B and C). NS-398 did not change metastasis 
regardless of the schedule (Figure 5D). Aspirin and SC-560, but not 
NS-398, reduced the number of tumor cells in the lung 24 hours 
after injection (Figure 5, E and F). A similar reduction was obtained 
in COX-1–/– mice (Figure 5, E and F). These findings suggest that 
COX-1 in host cells, rather than in tumor cells, is required for the 
pulmonary retention of tumor cells and the onset of metastasis.
TXA2 signaling driven by COX-1 is essential for metastasis. Cir-
culating TXA2 is the most abundant product of COX-1 in the 
circulatory system, mainly produced by activated platelets (4). 
To ask whether TXA2 was a critical intermediary in the COX-1–
dependent development of metastasis, we administered picot-
amide (PICO), a dual inhibitor of TXAS and antagonist of TXA2 
receptor (TP), to mice (Figure 6A) (44). This treatment reduced 
mice had decreased serum TXB2 levels (Figure 4C) and reduced 
platelet aggregation (Figure 4, D and E) compared with COX-1+/+ 
mice. Taken together, these data indicate that the inhibition of 
COX-1 is sufficient to impair metastasis development. They fur-
ther suggest that inhibition of COX-1 mimics the antimetastatic 
effect of aspirin. These results led us to ask (a) what phase of 
metastasis is affected by inhibition of COX-1; (b) which product of 
COX-1 enables metastasis; and (c) which COX-1–expressing cells 
are responsible for these effects.
Activity of COX-1 is required during the intravascular phase of 
metastasis. Disseminating tumor cells remain in the bloodstream 
for 1–4 days prior to extravasation, a time that varies depending 
on the model used (43). After tail vein injection, B16F10 cells were 
mainly intravascular after 24 hours and underwent extravasation 
between days 1 and 3 with the majority extravasated by day 4 (Sup-
plemental Figure 5, A and B). The number of B16F10 cells rapidly 
decreased after injection, with only approximately 25% of the total 
adhered cells surviving in the lung vasculature 1 day after injection 
(Supplemental Figure 5C). Multicellular colonies were first noted 
on day 3, and micrometastases were seen on day 4 (Supplemental 
Figure 5, C and D). With day 0 being the day of injection, treatment 
Figure 3. The inhibition of COX-1 is sufficient to reduce metastasis. (A and B) Concentration of TXB2 in serum (n = 3) (A) or PGE2 in LPS-stimulated plasma 
(n = 4) (B; see also Figure 1E) from mice treated with vehicle, SC-560, or NS-398 for 2 days. (C and D) B16F10 metastatic lung nodules in lungs from C57BL/6 
mice treated with vehicle or drugs (n = 16, 12, and 16) as in Figure 2A. (E and F) Relative area (E) and representative images (F) of metastatic nodules from 
H&E-stained lung sections (F) (n = 4, 3, and 4; ≥3 nodules per lung). Scale bar: 700 μm. (G–J) Single disseminated tumor cells in lungs and metastatic 
lung nodules (G and H) and liver metastases (I and J) in BALB/c mice bearing 4T1-GFP tumors, treated with vehicle or SC-560 (n = 8 and 7), as in Figure 2E. 
Control groups are the same as in Figure 2, F and H. Data are represented as mean + SD. One-way ANOVA with Tukey’s multiple-comparisons test. *0.01 < 
P ≤ 0.05; **0.001 < P ≤ 0.01; ***P ≤ 0.001.
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26, 45). Fluorescently labeled B16F10 cells (B16F10-CMAC) and 
platelets (Plts-PKH26) were injected into the opposite tail veins of 
mice. Platelet aggregation was observed only in the vicinity of the 
tumor cells, not distantly (Supplemental Figure 7A), suggesting 
that aggregation was triggered by the tumor cells. Additionally, 
platelets neither aggregated nor associated with the lung vas-
culature of naive mice (Supplemental Figure 7B), excluding the 
possibility that platelet aggregation resulted from euthanasia and 
its accompanying decreased blood flow. Treatment with aspirin, 
SC-560, and picotamide, but not NS-398, decreased the number 
and the size of clots per tumor cell (Figure 8, A–C). Similar results 
were obtained after coincubation of the 2 cell populations in vitro 
(Supplemental Figure 8, A–C). Pretreatment of platelets with aspi-
rin and SC-560 diminished platelet aggregation on tumor cells, 
while pretreatment of tumor cells had no effect (Supplemental 
Figure 8, D–F). Additionally, COX-1+/+ platelets, but not COX-1–/– 
platelets, B16F10 cells, nor primary lung microvascular endothe-
lial cells (LMVECs) cells, generated TXB2 either alone or in cocul-
ture (Figure 8D). Thus, COX-1 in platelets associated with B16F10 
cells is a major source of TXA2, and its inhibition affects platelet 
aggregation and thrombus expansion on tumor cells.
We then asked whether COX-1 inhibition in reintroduced plate-
lets would reduce metastasis. After platelet depletion by R300 anti-
body, platelets isolated from vehicle-, ASA-, SC-560–, NS-398–, or 
PICO-treated mice or COX-1–/– mice were infused after the antibody 
had dissipated but before platelets regained control levels (Supple-
mental Figure 9, A and B). Platelet depletion inhibited metastasis 
formation by B16F10 cells (Supplemental Figure 9C) (26, 45). The 
reinfusion of COX-1+/+ platelets in both COX-1+/+ (Figure 8, E and F) 
and COX-1–/– (Supplemental Figure 9D) mice resulted in significantly 
greater pulmonary retention of tumor cells at 24 hours and enhanced 
numbers of metastatic lung colonies (Figure 8, G and H) compared 
with using COX-1–/– platelets. Similarly, infusion of platelets from 
ASA-, SC-560–, and PICO-treated mice (Figure 8, G and H) or 
plasma levels of TXB2 (Figure 6B) and platelet aggregation (Fig-
ure 6, C and D), demonstrating inhibition of TXAS activity and 
TXA2/TP signaling. Treatment of mice with picotamide signifi-
cantly reduced the number of B16F10 (Figure 6, E and F) and 4T1 
(Supplemental Figure 3B) metastatic lung nodules. Picotamide 
treatment during the intravascular phase of metastasis (PICO 
–2→+1) reduced the number of metastatic lung nodules (Figure 
6G) and decreased the early retention of tumor cells in the lungs 
(Figure 6, H and I). Furthermore, picotamide decreased the num-
ber of spontaneous metastases to liver and lungs, the number 
of disseminated tumor cells in the lungs (Figure 6, J and K), and 
the number and invasive capacity of CTCs (Supplemental Figure 
4, B–E). Similarly, the TP antagonist vapiprost reduced platelet 
aggregation but not plasma TXA2 (Supplemental Figure 6, A–C), 
compatible with TP antagonism. Vapiprost impaired the early per-
sistence of tumor cells in the lungs (Supplemental Figure 6, D and 
E), further supporting the notion that TXA2 signaling is required 
for early phases of metastatic seeding.
We then supplemented TXA2 using U46619, restoring basal 
levels of plasma TXA2/TXB2 (Figure 7A) and platelet aggrega-
tion (Figure 7, B and C) in aspirin-treated mice. This restored the 
numbers of persistent tumor cells in the lung to control values in 
aspirin-treated mice 1 day after injection (Figure 7, D and E) and 
of experimental metastases, even when U46619 was discontin-
ued 1 day after tumor cell injection (Figure 7, F–H). These results 
suggest a central role for COX-1–derived TXA2 in the inhibition 
of metastasis by aspirin.
TXA2 synthesis by COX-1 in platelets is required for metastasis. 
TXA2 is synthesized by activated platelets and is a potent agonist 
of platelet aggregation and a secondary mediator of thrombus 
expansion (4). Platelets aggregate on the surface of B16F10 cells 
through a TF-dependent mechanism (27). We asked whether inhi-
bition of COX-1 leading to reduced TXA2 levels results in decreased 
aggregation of platelets on tumor cells and reduced metastasis (8, 
Figure 4. COX-1 deficiency decreases experimental lung metas-
tasis. (A and B) B16F10 metastatic lung nodules in COX-1+/+ 
(C57BL/6) or COX-1–/– mice (n = 7), as in Figure 2A. (C) Concen-
tration of serum TXB2 from COX-1
+/+ or COX-1–/– mice (n = 4). (D 
and E) Agonist-induced aggregation of platelets from COX-1+/+ or 
COX-1–/– mice (n = 8 and 4). Data are represented as mean + SD 
(A and C), median ± range (D). Unpaired t test, 2-tailed (A and 
C); 1-way ANOVA with Tukey’s multiple-comparisons test (D). 
*0.01 < P ≤ 0.05; **0.001 < P ≤ 0.01; ***P ≤ 0.001.
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platelet-poor plasma (Supplemental Figure 9C) did not restore lung 
metastasis formation. Platelets from NS-398–treated mice restored 
metastatic colony formation (Figure 8, G and H). Together these 
results establish platelets as the COX-1/TXA2–dependent compart-
ment in the establishment of metastasis.
Inhibition of COX-1 reduces the adhesion of tumor cells to endo-
thelium. Tumor cell adhesion to endothelial cells during hematog-
enous metastasis involves multiple mechanisms (46) and seems to 
be facilitated by interactions with platelets (47). We investigated 
tumor cell adhesion to monolayers of LMVECs in the presence of 
platelets under flow with a low shear stress of 0.05 dyn/cm2. Firm 
tumor cell adhesion to LMVECs was measured after the flow was 
increased to a higher shear stress (1 dyn/cm2) (Supplemental Fig-
ure 10, A and B). Platelet aggregates adhered to tumor cells and 
formed bridges between tumor cells and LMVECs (Supplemental 
Figure 10C). Aspirin and SC-560 reduced the adhesion of tumor 
cells to LMVECs and the association of platelets with tumor cells 
(Supplemental Figure 10, D–F, and Supplemental Video 1). While 
the higher shear stress did not alter adhesion of the tumor cells, 
interestingly, it produced a significant dissociation of platelets 
from tumor cells under aspirin and SC-560 treatment (Supple-
mental Figure 10, G–I). These data suggest that COX-1 inhibition 
can reduce the adhesion of tumor cells to the endothelium.
The COX-1/TXA2 axis in platelets contributes to an intravascu-
lar metastatic niche. Microemboli are formed with tumor cells, 
platelets, and myeloid cells at sites of activated endothelium. The 
myeloid cells promote the survival of disseminating cells and their 
development into metastasis (27, 29, 32, 48). Using Cx3cr1gfp/+ 
mice to visualize monocytes and macrophages (27, 49), we found 
that aspirin (medium and high doses) and SC-560, but not NS-398 
and picotamide, reduced clustering of monocytes/macrophages 
around the intravascular tumor cells (Figure 9, A and B). The 
magnitude of monocyte recruitment correlated with the extent 
of the platelet clots (Figure 9C). Treatment with aspirin, SC-560, 
and picotamide also reduced the extent of endothelial activation 
as indicated by E-selectin and VCAM-1 expression in vessels adja-
cent to platelet–tumor cell aggregates (Figure 9, D–F). Neither 
monocyte/macrophage recruitment nor endothelial activation 
was observed in naive mice (Supplemental Figure 7). Additionally, 
inhibition of COX-1/TXA2 was associated with a larger diame-
ter of lung vessels (Supplemental Figure 11, A–C), suggesting a 
decrease of vasoconstriction that might further prevent the accu-
mulation of aggregates.
Analogous effects resulted from coinfusion of COX-1–/– plate-
lets and B16F10 cells in COX-1+/+ mice, with a decrease in platelet 
aggregation on tumor cells (Figure 10, A–C), association of tumor 
Figure 5. COX-1 inhibition affects the intravascular phase of metastasis. (A) Experimental design. (B–D) Number of B16F10 metastatic lung nodules in 
C57BL/6 mice treated with vehicle or aspirin (B), SC-560 (C), or NS-398 (D), according to A. (B) n = 14, 11, 14, 6, and 6; (C) n = 12, 12, 10, 6, and 5; (D) n = 10, 16, 10, 
5, and 6. (E and F) Number of B16F10 cells (E) and representative tile scans (F; top panels, inverted look-up-table [LUT]; bottom panels, ×20 magnification) 
of the left lung of COX-1–/– (n = 5) or of C57BL/6 mice treated with vehicle, aspirin (low, medium, and high doses), SC-560, or NS-398 (n = 12, 6, 6, 8, 6, and 5). 
Whole left lungs were imaged 24 hours after injection of B16F10-CMFDA cells (white). Scale bars: 1 mm (black bar), 100 μm (white bar). Data are represented as 
mean + SD. One-way ANOVA with Tukey’s multiple-comparisons test. *0.01 < P ≤ 0.05; **0.001 < P ≤ 0.01; ***P ≤ 0.001.
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cells with activated endothelium (Figure 10, D–F), diameter of 
blood vessels (Supplemental Figure 11, D–F), and recruitment of 
monocytes/macrophages to tumor cells (Figure 10, G and H) in 
comparison with mice infused with COX-1+/+ platelets.
The COX-1/TXA2 pathway contributes to a pulmonary premet-
astatic niche. The ability of disseminated tumor cells to colo-
nize distant sites is enhanced by the systemic effects of a pri-
mary tumor, generating a premetastatic niche (50). To test the 
effect of inhibition of the COX-1/TXA2 pathway on the estab-
lishment of a lung premetastatic niche, mice bearing B16F10 
subcutaneous tumors were treated with aspirin and injected 
i.v. with tumor cells to induce lung metastasis before the occur-
rence of spontaneous metastasis (Figure 11A). Aspirin treatment 
was started after the initiation of tumor growth and interrupted 
2 days before tumor cell injection to avoid a direct effect of platelet 
inhibition on metastatic seeding. The increased numbers of meta-
static lung nodules, indicative of the establishment of a premeta-
static niche, were completely abrogated by treatment with aspirin 
(Figure 11B). Aspirin did not affect the number of nodules in mice 
without subcutaneous tumors (Figure 11B), further supporting the 
prometastatic role of intact COX-1/TXA2 axis in platelets at the 
moment of tumor cell injection.
Lung preconditioning has been linked to the recruitment of 
myeloid cells with the support of the coagulation system (27, 51, 
52). The numbers of Cx3CR1-GFP+ monocytes/macrophages in the 
lungs of mice bearing tumors were greater than those in lungs of 
naive mice. Aspirin abolished this increase in monocytes/macro-
phages in the premetastatic lungs (Figure 11, C and D) but did not 
affect the numbers in naive mice (Figure 11C). Taking into account 
the role of platelets in the recruitment of myeloid cells (27, 29, 33) 
and the effect of the TXA2 inhibitor picotamide on the establish-
ment of spontaneous metastasis (Figure 6, J and K), together these 
Figure 6. Inhibition of TXA2 signaling alters the intravascular phase of metastasis. (A) Diagram of the targets of picotamide (PICO) in platelets. 
(B) TXB2 in plasma from C57BL/6 mice treated with vehicle or picotamide for 2 days (n = 4). (C and D) Agonist-induced aggregation of platelets from 
C57BL/6 mice treated with vehicle or picotamide (n = 6 and 4). (E and F) B16F10 metastatic lung nodules in C57BL/6 mice treated with vehicle or 
picotamide (n = 6) as in Figure 2A. (G) B16F10 metastatic lung nodules in C57BL/6 mice treated with vehicle or picotamide, as in Figure 3A (n = 10, 14, 
10, 5, and 5). (H and I) Number of B16F10-CMFDA cells (white) (H) and representative tile scans (I) of the left lung of C57BL/6 mice treated with vehicle 
or picotamide (n = 12 and 6) 24 hours after the injection of tumor cells. Scale bars: 1 mm (black bar), 100 μm (white bar). (J and K) Single disseminated 
cells in lungs (J) and metastatic nodules in lungs (J) or liver (K) of BALB/c mice bearing a 4T1-GFP tumor, treated with vehicle or picotamide (n = 8), as 
in Figure 2E. Control groups are the same as in Figure 2, F and H. Data are represented as mean + SD (B, E, G, H, J, and K), median ± range (C). Unpaired 
t test, 2-tailed (B, E, and H); 1-way ANOVA with Tukey’s multiple-comparisons test (C, G, J, and K). *0.01 < P ≤ 0.05; **0.001 < P ≤ 0.01; ***P ≤ 0.001.
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specifically required, we tested clopidogrel, an antagonist of the 
P2Y12 ADP purinergic receptor, and eptifibatide, an inhibitor of 
αIIbβ3 integrin (also known as GPIIb/IIIa), both used clinically to 
reduce platelet aggregation (53–56). Clopidogrel and eptifibati-
de significantly reduced ADP-induced platelet aggregation (Fig-
ure 12, A and B) without affecting plasmatic TXB2 levels in vivo 
data suggest that the establishment of a lung premetastatic niche 
depends on the COX-1/TXA2 pathway in platelets.
TXA2 signaling, not other platelet activation pathways, is 
required for the establishment of the intravascular metastatic niche. 
To understand whether platelet aggregation generally is critical 
for creating a metastatic niche or whether TXA2 signaling is more 
Figure 7. TXA2 analog U46619 abrogates the inhibition of metastasis by aspirin. (A) Plasma TXB2 in mice treated with vehicle, aspirin (medium dose), or 
aspirin supplemented with U46619 (ASA + U46619; n = 4). (B and C) Agonist-induced aggregation of platelets from mice treated with vehicle, aspirin, or 
aspirin + U46619 (n = 5, 4, and 5). (D and E) Number of tumor cells (D) and representative tile scans (E) from left lungs of mice treated with vehicle, aspirin, 
or aspirin + U46619 (n = 6, 6, and 5) 1 day after injection (B16F10-CMFDA, white). Scale bars: 1 mm (black bar), 100 μm (white bar). (F) Experimental design 
of aspirin with or without U46619 treatment. Two days before B16F10 cell injection, mice were treated with vehicle, aspirin, or aspirin + U46619 for 3 weeks 
(ASA + U46619) or supplemented until 1 day after injection, followed by treatment with aspirin alone [ASA + (U46619 –2→+1)]. (G and H) B16F10 metastatic 
lung nodules in mice treated with vehicle, aspirin, aspirin + U46619, or aspirin + (U46619 –2→+1) (n = 9, 10, 9, and 8). Data are represented as mean + SD (A, 
D, and G), median ± range (B). One-way ANOVA with Tukey’s multiple-comparisons test. *0.01 < P ≤ 0.05; **0.001 < P ≤ 0.01; ***P ≤ 0.001.
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Discussion
In this paper we have provided evidence that aspirin reduces 
metastasis through the inhibition of platelet COX-1 and its prod-
uct TXA2. Inhibition of COX-1 activity or TXA2 signaling alone by 
pharmacological or genetic means was sufficient to reduce metas-
tasis in a range of models. This novel finding directly implicates 
the activity of COX-1/TXA2 in platelets before and during the 
intravascular transit of tumor cells, while it is not necessary for the 
persistent growth of the metastatic lung nodules. The inhibition of 
(Figure 12C), compatible with a functional COX-1/TXA2 path-
way in platelets. Unlike aspirin, clopidogrel and eptifibatide did 
not affect the early persistence of B16F10 melanoma cells in the 
lungs (Figure 12, D and E), suggesting that TXA2 signaling in the 
context of platelet aggregation is essential for the establishment 
of the early metastatic niche.
All together our data describe a signaling network centered on 
platelet-derived TXA2 that can be inhibited by aspirin treatment, 
leading to a reduced seeding efficiency and metastasis (Figure 13).
Figure 8. Platelet-derived TXA2 supports metastasis. (A–C) Maximum intensity projection (MIP, median filter) of 3D confocal stacks of tumor 
cells (B16F10-CMAC, white) and platelets (Plts-PKH26, red) and number (B) and volume (C) of platelet aggregates per tumor cells in whole lungs of 
Cx3cr1gfp/+ mice, treated with vehicle, aspirin (low, medium, and high doses), SC-560, NS-398, or picotamide (n = 3). Lungs were harvested 8 hours 
after injection. Scale bar: 30 μm. (D) Concentration of TXB2 in conditioned medium (CM) from cultures of B16F10 cells, LMVECs, and/or COX-1+/+ or 
COX-1–/– platelets (n = 3). (E and F) Number of tumor cells (E) and representative tile scans (F) of the left lung from platelet-depleted recipient mice 
(n = 5) at 1 day after i.v. injection of platelets (from COX-1–/– or COX-1+/+ donor mice) and tumor cells (B16F10-CMFDA cells, white). Scale bars: 1 mm 
(black bar), 100 μm (white bar). (G and H) B16F10 metastatic lung nodules from platelet-depleted mice reinfused with COX-1 or COX-1–/– platelets (n 
= 8) or COX-1+/+ platelets isolated from donor mice pretreated with vehicle, aspirin, SC-560, NS-398, or picotamide (n = 10, 9, 9, 5, and 9). Data are 
represented as mean + SD. One-way ANOVA with Tukey’s multiple-comparisons test (B–D and G); unpaired t test, 2-tailed (E). *0.01 < P ≤ 0.05; 
**0.001 < P ≤ 0.01; ***P ≤ 0.001.
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Aspirin has distinctive pharmacological properties at dif-
ferent doses, mainly derived from the differential inhibition 
of COXs in different body compartments. The antimetastatic 
effect of aspirin was seen at doses that inhibited COX-1/TXA2, 
whereas the inhibition of COX-2/PGE2 alone was not sufficient, 
COX-1/TXA2 in platelets impairs multiple consecutive steps of the 
hematogenous transit of tumor cells, leading to the reduction of 
tumor cells in the lung vasculature. Thus, COX-1 activity and TXA2 
production in platelets contribute to the generation of a permissive 
early metastatic niche (Figure 13).
Figure 9. COX-1/TXA2 inhibition impairs the establishment of a permissive intravascular niche. (A) MIP (median filter) of 3D confocal stacks (×20, 
top row) and surface reconstruction (bottom row) of tumor cells (B16F10-CMAC, white), platelets (Plts-PKH26, magenta), and Cx3CR1
+ monocytes/
macrophages (GFP, green) in whole lungs of Cx3cr1gfp/+ mice at 8 hours after injection of tumor cells and platelets. Scale bars: 50 μm. (B) Volume of 
monocyte/macrophage clusters (n = 3). (C) Correlation plot of the volume of monocyte/macrophage clusters versus the volume of clots within the 
cluster (n = 143). (D) MIP (median filter) of 3D confocal stacks of lung sections from Cx3cr1gfp/+ mice treated with vehicle or drugs and injected with 
tumor cells (B16F10-CMRA, white). Activated endothelial cells were immunofluorescently labeled with an anti–E-selectin (green) or anti–VCAM-1 
(magenta) antibody. Scale bar: 50 μm. (E and F) Number of tumor cells within an 80-μm radius from E-selectin– or VCAM-1–expressing vessels (E) 
(32) and fluorescence intensity of E-selectin or VCAM-1 (F) (n = 3). Data are represented as mean + SD. One-way ANOVA with Tukey’s multiple- 
comparisons test. *0.01 < P ≤ 0.05; **0.001 < P ≤ 0.01; ***P ≤ 0.001.
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Figure 10. TXA2 from platelets mediates the generation of the prometastatic intravascular niche. (A–C) MIP (median filter) of 3D confocal stacks of 
tumor cells (B16F10-CMAC, white) and platelets (Plts-PKH26, red) in lungs of platelet-depleted Cx3cr1gfp/+ mice (A) and quantification of the number (B) 
and volume (C) of clots per tumor cell (n = 3), at 8 hours after injection of tumor cells and COX-1+/+ or COX-1–/– platelets. Scale bar: 10 μm. (D–F) MIP (median 
filter) of 3D confocal stacks of lung sections labeled for E-selectin (green) and VCAM-1 (magenta) (D), number of tumor cells associated with E-selectin– 
or VCAM-1–expressing vessels (E), and fluorescence intensity of E-selectin or VCAM-1 (F) (n = 3) in lung sections from platelet-depleted Cx3cr1gfp/+ mice 
injected with tumor cells and COX-1+/+ or COX-1–/– platelets. Scale bar: 50 μm. (G and H) MIP of 3D confocal stacks (×20, top row) and surface reconstruction 
(bottom row) of tumor cells (B16F10-CMAC, white), platelets (Plts-PKH26, magenta), and Cx3CR1
+ monocytes/macrophages (GFP, green) (G) and quantifi-
cation of the volume of monocyte/macrophage clusters (H) (n = 3) in whole lungs of platelet-depleted Cx3cr1gfp/+ mice injected with tumor cells and COX-1+/+ 
or COX-1–/– platelets. Scale bars: 50 μm. Data are represented as mean + SD. Unpaired t test, 2-tailed. *0.01 < P ≤ 0.05; ***P ≤ 0.001.
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monocytes/macrophages in proximity to the tumor cells (32, 61). 
Monocyte chemoattractant protein-1 (CCL2/MCP-1) and CCL5 
release by endothelial cells following TXA2 signaling might amplify 
recruitment (29, 64). Altogether, local release of TXA2 leads to 
the formation of hematogenous microemboli with prometastatic 
properties. The recruitment of monocytes/macrophages was also 
reduced by aspirin at the level of the premetastatic niche, leading to 
reduced lung seeding. These data support the notion that cancer- 
induced thrombosis via the COX-1/TXA2 pathway plays a central 
role in the conditioning of metastatic sites both before and after the 
arrival of CTCs (27).
The inhibition of COX-2 decreases metastasis in some models 
(10, 11) but not others (12). In our experiments, NS-398 did not 
reduce seeding of B16F10- and 4T1-derived lung metastasis, 
but it decreased the size of metastatic lung nodules from 
B16F10 cells, consistent with COX-2 enhancing proliferation 
and immune evasion in experimental models (65, 66). We noted 
that inhibition of COX-2 significantly inhibited metastasis by 
one colorectal cancer cell line, MC-38-GFP. Some colorectal 
cancers depend on COX-2 for progression (66), and we con-
firmed that MC-38 cells express much higher levels of COX-2 
than B16F10 cells (S. Lucotti, unpublished observations). Thus, 
the sensitivity to COX-2 inhibition might be indicated by COX-2 
expression in cancer cells (67).
In contrast, our data point to COX-1 inhibitors reducing 
metastasis through a microenvironment-centered mechanism. 
COX-1 inhibition was effective on cell lines regardless of their 
COX-1 expression (S. Lucotti, unpublished observations), and 
COX-1–/– mice had reduced metastasis, suggesting that aspirin 
has an antimetastatic effect independent of tumor cell expression 
of COX-1. Using Oncomine gene expression data we found that 
COX-1 expression in the primary tumor did not correlate with risk 
of metastatic cancer nor with the antimetastatic effect of aspirin 
suggesting a prominence of COX-1 rather than COX-2 in the 
metastatic process. We exclude COX-independent targets (57) 
since analogous results were obtained with inhibitors of other 
steps in the COX pathway and in COX-1–/– mice. The antimeta-
static effect of aspirin was seen in low- and medium-dose trials 
(75–300 mg/d), and increased doses did not show additional 
benefit (23), consistent with platelet COX-1 as the main target 
for the antimetastatic effect of aspirin. To the best of our knowl-
edge, COX-1 has been previously implicated only marginally in 
the development of metastasis (58). COX-1 can be expressed by 
a variety of cell types (21). Reinfusion of platelets in platelet- 
depleted mice only restored metastasis if the platelets contained 
active COX-1, showing that it is the platelet supply of COX-1 that 
is essential to metastasis.
Further, although COX-1 can generate a variety of active prosta-
glandins, the reduction of TXA2 is responsible for the antimetastatic 
effect of aspirin. Infusion of a synthetic analog of TXA2 restored the 
metastatic phenotype during aspirin treatment. Platelets aggregate 
on the surface of tumor cells and function as circulating reservoirs 
of TXA2. Autocrine TXA2 signaling in platelets further enhances 
their aggregation on tumor cells, which supports metastasis (8, 26, 
45). Additionally, paracrine TXA2 signaling generates a favorable 
environment for tumor cell seeding through vascular constriction 
and induction of E-selectin and VCAM-1 through the TP receptor 
on endothelial cells (59, 60). Cytokines released from intracellular 
granules of activated platelets also induce endothelial cell activa-
tion (61). Endothelial activation correlates with tumor cell survival 
within the lung vasculature (32), and E-selectin and VCAM-1 might 
facilitate tumor cell adherence to the endothelium directly (62) or 
via bound platelets (63). We demonstrated enhanced adhesion of 
tumor cells to an LMVEC monolayer in the presence of platelets, 
analogous to the results in vivo. Concomitantly, endothelial activa-
tion facilitates the homing and retention of metastasis-promoting 
Figure 11. The COX-1/TXA2 pathway is 
required for the establishment of the 
premetastatic niche. (A) Experimental 
design. (B) Number of B16F10 metastatic 
lung nodules in C57BL/6 mice bearing 
no tumor (naive) or subcutaneous 
B16F10 tumor (SC), treated with vehicle 
or aspirin (medium dose) as in A (n = 
5, 3, 5, and 5). (C and D) Numbers of 
GFP+ monocytes/macrophages per field 
of view (FOV) in naive or SC Cx3cr1gfp/+ 
mice treated with vehicle or aspirin (C), 
and representative confocal images of 
lung sections from mice (D). Lungs were 
harvested 11 days after s.c. inoculation 
of tumor cells, before i.v. injection of 
B16F10 cells (n = 3). Scale bar: 200 μm. 
Data are represented as mean + SD. One-
way ANOVA with Tukey’s multiple-com-
parisons test. *0.01 < P ≤ 0.05; **0.001 < 
P ≤ 0.01; ***P ≤ 0.001.
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However, aspirin significantly increases the risk of severe gas-
trointestinal symptoms and complications, especially over long-
term use. Our data, together with previous clinical trials (71–73), 
suggest that selective TXA2 inhibitors such as picotamide might 
present an alternative to target platelet TXA2 while sparing other 
gastroprotective COX-1 products (i.e., PGI2), and thus might be a 
safer therapeutic option for the prevention of metastatic disease.
Methods
Animals. C57BL/6 (C57BL/6J), BALB/c (BALB/cAnNCrl), and SCID 
(CB17/Icr-Prkdcscid/IcrIcoCrl) mice were purchased from Charles River 
Laboratories and Cx3cr1gfp/+ mice (B6.129P-Cx3cr1tm1Litt/J) from The 
Jackson Laboratory (49). COX-1–/– mice (74) were provided by TDW 
and JAM. Seven- to ten-week-old female mice were used for experi-
ments involving drug treatment and/or tumor cell injection, while 
older naive mice with a C57BL/6 background were used for blood 
withdrawal and platelet isolation. Drugs were administered through 
drinking water, given ad libitum and changed every second day.
Cell lines and staining. B16F10 murine melanoma cells (a gift from 
John L. Francis, Center for Thrombosis Research, Florida Hospital, 
Orlando, Florida, USA; ref. 75) were cultured in RPMI 1640 medium 
(Sigma-Aldrich), 4T1/4T1-GFP murine breast cancer cells, MC-38-
GFP murine colorectal cancer cells, and MDA-MB-231-CFP human 
breast cancer cells (ATCC) were cultured in DMEM (Sigma-Aldrich) 
in a 5% CO2 humidified atmosphere at 37°C. Media were supple-
mented with 10% heat-inactivated FBS (Gibco), 2 mM l-glutamine, 
25 mM HEPES, 50 U/ml penicillin, and 5 μg/ml streptomycin (Ther-
(Supplemental Figure 12). These data are consistent with the 
hypothesis that tumor cells with higher procoagulant activity are 
more sensitive to the antimetastatic effect of COX-1 inhibition (11, 
24). We showed that aspirin only at doses inhibiting COX-1 and 
specific COX-1 inhibitors blocked metastasis in 4 different metas-
tasis models as well as spontaneous metastasis by 4T1. A limitation 
of our study, however, is that we only detailed the mechanisms for 
B16F10 melanoma cells. We could hypothesize that a similar inhi-
bition of platelet COX-1 would occur in a range of models.
It is well established that platelet function greatly supports 
metastatic spread (68). Pharmacological or genetic inhibition of 
P2Y12 receptor and αIIbβ3 integrin has been previously found to be 
associated with reduced numbers of experimental metastasis (53, 
55, 56). We failed to find any effect of the P2Y12 receptor antago-
nist clopidogrel and the αIIbβ3 integrin inhibitor eptifibatide on the 
early metastatic seeding of B16F10 cells. These findings suggest 
that alternative pathways of platelet aggregation are not required 
for the establishment of the intravascular metastatic niche, but 
they do not exclude the possibility that these pathways support 
later stages of metastasis such as epithelial-mesenchymal transi-
tion and extravasation (55, 69).
Overall, this work identifies COX-1 and its product TXA2 as 
potential pharmacological targets to inhibit the intravascular 
phase of metastasis, consistent with the use of low- to medium- 
dose aspirin as adjuvant therapy for cancer patients. The recently 
started phase III ADD-ASPIRIN Trial (70) will examine the effects 
of aspirin in the prevention of tumor relapse and metastasis. 
Figure 12. Platelet activation pathways other than COX-1/TXA2 are not required for early metastatic seeding. (A and B) ADP-induced aggregation of 
CD61-stained platelets from C57BL/6 mice treated with vehicle, clopidogrel, or eptifibatide for 2 days (n = 4). (C) TXB2 in plasma from mice treated with 
vehicle or drugs for 2 days (n = 4, 3, 3, and 4). (D and E) Number of B16F10-CMFDA cells (white) (D) and representative tile scans (E) of the left lung of 
C57BL/6 mice treated with vehicle or drugs (n = 10, 6, 6, and 5), imaged at 24 hours after the injection of tumor cells. Scale bars: 1 mm (black bar), 100 μm 
(white bar). Data are represented as median ± range (A), mean + SD (C and D). One-way ANOVA with Tukey’s multiple-comparisons test. *0.01 < P ≤ 0.05; 
**0.001 < P ≤ 0.01.
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sterile water and delivered in saline at 0.5 mg/kg/d 
through i.p. injection (78).
Isolation and staining of platelets. After sacrifice 
with an overdose of pentobarbital (665 mg/kg, i.p., 
or 332.5 mg/kg, i.v.), blood was collected from mice 
by cardiac puncture in syringes containing 3.2% (wt/
vol) sodium citrate (Thermo Fisher Scientific) or 
ACD buffer (83 mM Na3C6H5O7, 111 mM dextrose, 71 
mM citric acid) (Sigma-Aldrich and Fisher Thermo 
Scientific), at 1:10 vol/vol ratio to blood.
To test aggregation, citrated blood was diluted 1:2 
with modified Tyrode’s-HEPES (MTH) buffer (134 
mM NaCl, 0.3 mM NaH2PO4•2H2O, 3 mM KCl, 5 mM 
HEPES, 5 mM dextrose, 2 mM MgCl2) (Sigma-Aldrich and Fisher Ther-
mo Scientific) supplemented with 0.02 U/ml apyrase (Sigma-Aldrich) 
and 0.25 μM PGE1 (Alprostadil, Sigma-Aldrich). After centrifugation at 
180 g for 10 minutes at 22°C, the supernatant was collected (platelet-rich 
plasma [PRP]). The remaining pellet was centrifuged at 12,000 g for 2 
minutes at room temperature, and the supernatant was collected (plate-
let-poor plasma [PPP]).
To prepare washed platelets, PRP was diluted with washing 
buffer (10% MTH vol/vol in dH2O, 0.10% wt/vol NaHCO3, 0.20% 
wt/vol BSA, and 1 mM EGTA) and centrifuged at 1300 g at 22°C for 
10 minutes. The platelet pellet was washed twice with washing buf-
fer containing 0.25 μM PGE1. Platelets were counted in a Coulter 
counter (Beckman; 50-μm aperture tube, 3–30 fl particles). Washed 
platelets (8 × 105 cells/μl) were stained with PKH26 (Sigma-Aldrich) 
and readjusted to the required concentration in PPP or resuspen-
sion buffer (10% MTH vol/vol in dH2O, 0.10% wt/vol NaHCO3, and 
0.20% wt/vol BSA).
Platelet aggregometry. Platelet aggregation was evaluated as previ-
ously described (79). Briefly, citrated PRP was incubated with agonists 
arachidonic acid (1 μM; Sigma-Aldrich), U46619 (0.3 μM; Tocris), and 
ADP (1 M; ChronoLog) or their vehicles in half-area-96-well microtiter 
plates for 5 minutes at 37°C under 1 mm orbital shaking (Infinite m200 
plate reader, Tecan). Aggregated PRP was diluted 1:4 with ACD buf-
fer and labeled with anti-CD61–APC antibody (104316, BioLegend) 
for 30 minutes at 4°C. Samples were then diluted with 0.01% neutral 
buffered formalin in PBS (Sigma- Aldrich) and supplemented with 104 
CountBright absolute counting beads (Thermo Fisher Scientific). The 
suspension was analyzed with a FACSCalibur flow cytometer (BD 
Biosciences). Beads (FL1/SSC-H) were gated and platelets (FL4-H/
SSC-H) were acquired until the count of 100 beads was reached. The 
total number of single platelets was calculated using FlowJo software 
mo Fisher Scientific), with addition of 0.4 mg/ml G418 or 5 μg/ml 
puromycin for 4T1-GFP and MC-38-GFP cells, respectively. Primary 
LMVECs were cultured in 2% gelatin–coated flasks (Sigma-Aldrich) 
in enriched DMEM (76). Cells were passaged using Versene (B16F10) 
(Thermo Fisher Scientific) or 0.05% trypsin-EDTA solution (all other 
cell lines) (Sigma-Aldrich). LMVECs were used within 10 and tumor 
cells within 20 passages and routinely tested for mycoplasma contam-
ination (MycoAlert Mycoplasma Detection Kit, Lonza Group Ltd.). 
Exponentially growing B16F10 cells (50%–60% confluence) were 
stained with 12.5 μM solution of CellTracker Blue CMAC, Orange 
CMRA, or Green CMFDA dye (Thermo Fisher Scientific), following 
the manufacturer’s instructions.
Drug formulation for animal studies. Aspirin (ASA), purchased as 
dl-lysine acetylsalicylate (Aspégic injectable, Sanofi Aventis), was dis-
solved in sterile deionized water and resuspended in drinking water at 
30 mg/l (low) (37), 180 mg/l (medium) (38), or 625 mg/l (high) (8). 
SC-560 (Cayman Chemical) dissolved in DMSO (Sigma-Aldrich) was 
resuspended at 24 mg/l in drinking water supplemented with 0.2% (vol/
vol) polyethylene glycol 200 (PEG200) and 0.01% (vol/vol) Tween-20 
(both from Sigma-Aldrich) (77). NS-398 (Cayman Chemical) dissolved 
in DMSO was resuspended at 12 mg/l in drinking water supplemented 
with 0.9% wt/vol sodium chloride (Sigma-Aldrich) (77). Picotamide 
(PICO; Abcam) dissolved in 100% ethanol (Sigma- Aldrich) was resus-
pended in drinking water at 30 mg/l. U46619 (Cayman Chemical) was 
diluted in DMSO and delivered at 50 μg/kg through a 180-mg/l aspirin 
solution. Vapiprost (Vapiprost hydrochloride, Santa Cruz Biotechnolo-
gy) dissolved in sterile water was resuspended in drinking water at 20 
mg/l. All drinking water contained 2% wt/vol sucrose (Sigma-Aldrich). 
Clopidogrel [(±)-Clopidogrel (hydrochloride), Cayman Chemical] dis-
solved in 100% ethanol was delivered in saline at 10 mg/kg/d through 
i.p. injection (56). Eptifibatide (Sigma- Aldrich) was resuspended in 
Figure 13. Platelet-derived TXA2 promotes metastasis 
by generating a permissive intravascular metastatic 
niche. Model of metastasis promotion by TXA2 derived 
from COX-1 activity in platelets. The aggregation of 
platelets on tumor cells stimulates the aspirin-sen-
sitive de novo synthesis of TXA2, which enhances the 
expansion of clots on tumor cells and leads to further 
TXA2 synthesis. Concomitantly, TXA2-TP interaction 
induces the contraction of vascular smooth muscle cells, 
the activation of endothelial cells, and the recruitment 
of monocytes/macrophages to tumor cells, providing a 
permissive niche for metastasis seeding.
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Spontaneous metastasis assay. 5 × 105 4T1-GFP cells were injected 
s.c. in the right flank of female BALB/c mice. Tumors were measured 
using a digital caliper, and the volume was calculated as height × 
length × width × π/6. When the tumor reached 20–30 mm3, mice were 
randomly allocated to 4 treatment groups (vehicle, aspirin, SC-560, 
or picotamide). When tumor reached 800 mm3, lungs were perfused/
isolated for ex vivo imaging of the left lung. Lung and liver metastatic 
nodules were counted.
Isolation of CTCs and Transwell invasion assay. Blood from BAL-
B/c mice was drawn in syringes containing ACD buffer (1:5 vol/
vol). Whole blood was diluted in an equal volume of PBS, layered on 
Ficoll-Paque PLUS media solution (GE Healthcare), and centrifuged 
at 400 g for 30 minutes at 19°C, according to the manufacturer’s 
instructions. The mononuclear cell layer was isolated, and GFP+ cells 
were counted as CTCs.
For Transwell migration and invasion assays, 5000 CTCs were 
resuspended in serum-free DMEM and seeded on a Transwell insert 
(8 μm pore size; BD Biosciences) coated with growth factor reduced 
Matrigel matrix (2 μg/μl; BD Biosciences). The bottom chamber con-
tained DMEM supplemented with 2% FBS as chemoattractant. After 
20 hours, cells adherent to the bottom well were fixed with 2% PFA, 
and GFP+ cells were counted with a Celigo S Imaging Cytometer 
(Nexcelom Bioscience LLC).
Premetastatic niche formation assay. 5 × 103 B16F10 cells were injected 
s.c. in the back of female C57BL/6 or Cx3cr1gfp/+ mice. Two days after the 
tumor became palpable (12–15 days from injection), mice were treated 
with aspirin (medium dose) for 5 days. Treatment was interrupted 2 days 
before the i.v. injection of 2.5 × 105 B16F10 cells. Lungs were collected 
either just before (Cx3cr1gfp/+ mice, recruitment of myeloid cells) or 2 
weeks after tumor cell injection (C57BL/6, metastatic lung nodules).
Isolation and culture of LMVECs. Primary LMVECs were isolated 
as previously described (76). Briefly, lungs from female C57BL/6 mice 
were dissected, digested in a 0.5-mg/ml collagenase solution for 1 hour 
at 37°C, and filtered through a 70-μm cell strainer (Thermo Fisher Sci-
entific). Suspended cells were washed, blocked with 10 μg/ml murine 
IgG (I5381, Sigma-Aldrich), and stained with isolectin-B4–FITC (L2895, 
Sigma-Aldrich), anti-CD31–PE (102408, BioLegend), and anti-CD105–
APC (120414, BioLegend) antibodies, diluted to 1 μg/ml in PBS with 
2.5% FBS. Isolectin-B4+CD31+CD105+ cells were sorted using a Beck-
man Coulter Legacy MoFlo MLS High Speed Cell Sorter and cultured.
Measurement of prostanoids. After 2 days of treatment with vehi-
cle or drugs, blood was collected through the vena cava of terminally 
anesthetized C57BL/6 mice. For serum, blood was left to clot for 30 
minutes at room temperature and centrifuged at 850 g for 15 minutes 
at 4°C. For plasma, blood collected with ACD buffer (1:10 vol/vol) was 
centrifuged at 1000 g for 15 minutes at 4°C. B16F10 cells (3 × 104) and/
or platelets (50 × 106) were coincubated for 24 hours, followed by cen-
trifugation of conditioned medium at 1300 g for 10 minutes to remove 
detached cells and platelets. TXB2 concentration was measured 
through a Thromboxane B2 EIA kit (Cayman Chemical). 6-Keto-PG-
F1α concentration was measured in anticoagulated plasma through a 
6-keto-PGF1α ELISA kit (Enzo Life Sciences).
For ex vivo PGE2, whole anticoagulated blood was incubated with 
10 μg/ml LPS (Sigma-Aldrich) or saline for 24 hours at 37°C. Plasma 
was assayed with a PGE2 ELISA kit (Abcam). For in vivo PGE2, C57BL/6 
mice were injected with 5 mg/kg LPS or saline, and anticoagulated 
blood was collected through vena cava 4 hours after injection. Plasma 
(version 7.6.5). Depletion of the single-platelet population is repre-
sentative of platelet aggregation, and can be visualized through the 
appearance of a comet tail of platelet aggregates (79).
Ex vivo platelet aggregation on tumor cells. CMFDA-stained B16F10 
cells were seeded at 104 cells per well in collagen I–biocoated multi-
chambers (BD Biosciences). The following day, 30 × 106 PKH26-stained 
platelets were added together with vehicle or drugs. After 2 hours, cells 
were fixed with 2% paraformaldehyde (PFA) in PBS and mounted with 
Vectashield mounting medium containing DAPI (Vector Laboratories). 
Tumor cells and platelets were pretreated with vehicle or drugs for 2 
hours at 37°C or 30 minutes at 30°C, respectively, washed twice with 
PBS or washing buffer, and coincubated.
Experimental lung metastasis assay. B16F10 (2.5 × 105) and MC-38-
GFP (3.0 × 105) cells were injected i.v. into C57BL/6 mice, 4T1 (1.5 × 105) 
into BALB/c mice, and MDA-MB-231-CFP (1 × 106) into SCID mice. R300 
antibody (0.5 mg/kg; Emfret) for platelet depletion or isotype control 
(C301, Emfret) was injected i.p. 24 hours before i.v. injection of tumor 
cells and PPP (<1 × 106 platelets), PRP, or platelets (6 × 108 platelets). After 
2 weeks (4T1 cells), 3 weeks (B16F10 and MC-38-GFP cells), or 4 weeks 
(MDA-MB-231-CFP cells), mice were anesthetized (pentobarbital, 70 
mg/kg, i.p.) and their lungs artificially ventilated through a tracheotomy. 
After sacrifice, lungs were perfused through the pulmonary artery with 
Krebs-Ringer buffer (KRB) (4.74 mM KCl, 1.17 mM MgSO4•7H2O, 1.27 
mM CaCl2•2H2O, 1.18 mM KH2PO4, 118.4 mM NaCl, 24.87 mM NaHCO3, 
10 mM dextrose, 5% wt/vol dextran) (Sigma-Aldrich or Thermo Fisher 
Scientific). After clearance of blood, lungs were immersed in 10% neutral 
buffered formalin (Sigma-Aldrich). Metastatic lung nodules were visually 
counted (B16F10, MC-38-GFP, and 4T1 cells) or assessed by MRI scan 
(MDA-MB-231-CFP cells). Lobes were embedded in paraffin, and 5-μm 
sections were stained by H&E.
MRI scan of lungs. MRI on formalin-fixed lungs embedded in 4% 
agarose was performed at 4.7T or 7.0T (VNMRS, Agilent) using a 
25-mm-inner-diameter quadrature birdcage coil (Rapid). T2-weighted 
fast spin echo 3D scan was acquired (echo spacing 9.35 ms, echo train 
length 8, effective echo time [TE] 37.41 ms, repetition time [TR] 200 
ms) with a field of view (FOV) of 32 × 32 × 32 mm3 to ensure complete 
coverage of the coil (and sample). Scan time was approximately 27 min-
utes per sample for an isotropic resolution of 125 μm. Ten samples were 
queued for unsupervised MRI measurement using an in-house-devel-
oped carriage system utilizing a stepper motor driven by an Arduino 
controller (http://www.arduino.cc). Tumor burden was quantified by 
manual segmentation via ImageJ (version 1.46r, NIH) and itk-SNAP 
software (version 3.6.0) (80).
Ex vivo whole lung imaging assay. CMAC-stained B16F10 cells 
(5 × 105) and PKH26-stained platelets (9 × 108) were injected into 
opposite tail veins of Cx3cr1gfp/+ mice. After 8 or 24 hours, isolated 
lungs were placed in a specially designed chamber with a coverslip 
glass (0.16–0.19 mm thick) at its bottom. To visualize lung endo-
thelium, anti-CD31–PE antibody (50 mg/kg; 102408, BioLegend) 
was injected in the vena cava 5 minutes before sacrifice, followed 
by vena cava ligation. Lungs were inflated with 0.5 ml of air and 
remained inflated during the imaging (27, 31, 81). Tumor cell extrav-
asation was evaluated visually from microscopic FOV or through 
reconstruction of tumor cells and vessel surface with Imaris soft-
ware (versions 8.2 and 9, Bitplane). The size of platelet microclots 
and monocyte/macrophage clusters was calculated through MAT-
LAB (R2017a) code written in-house.
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Alexa Fluor 633) or a gallium arsenide phosphide (GaAsP) array (PE, 
Cx3CR1-GFP). Channels were acquired sequentially to minimize 
bleed-through of emitted light. Stacks of 15–40 slices at 1- to 2-μm 
intervals from random FOV or tile scans of whole left lung (×10 or 
×20) were acquired.
Statistics. Statistical analysis was performed with GraphPad 
Prism (version 5.02). D’Agostino and Pearson omnibus normality 
test was applied to assess data distribution. For normally distrib-
uted data, unpaired t test (2-tailed) or 1-way ANOVA with Tukey’s 
test or Pearson’s test was used. For non-normally distributed data, 
Mann-Whitney test, Kruskal-Wallis with Dunn’s multiple-compari-
sons post hoc test, or Spearman’s test was used. Outliers were iden-
tified through Grubbs’s test (α = 0.05, GraphPad QuickCalc outlier 
calculator) and excluded. Differences were considered significant 
with a P value lower than 0.05.
Study approval. Animal procedures were in accordance with UK 
Animal law (Scientific Procedures Act 1986), including local ethics 
approval at the University of Oxford under project license 30/3413.
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PGE2 was assayed through a PGE2 Metabolite EIA kit (PGE2M, Cay-
man Chemical), which measures 13,14-dihydro-15-keto-PGA2 and 
13,14-dihydro-15-keto-PGE2 metabolites.
Measurement of urinary salicyluric acid. Urine was collected from 
restrained C57BL/6 mice 2 weeks after i.v. injection of B16F10 and sup-
plemented with indomethacin (10 μg/ml in DMSO; Sigma- Aldrich). 
Urine was centrifuged at 10,000 g for 15 minutes at 4°C. Five micro-
liters of urine was mixed with 50 μl 6-methoxysalicylate (internal 
standard, 10 μM) and 1 ml formic acid (10 mM). To measure salicy-
luric acid (SUA), a 5-μl sample was injected onto the HPLC (Waters 
2695) equipped with a Micromass Quattro Micro Mass spectrometer 
(Waters). Separation was achieved using a Kinetex XB (2.6 μm, 2.1 × 
50 mm) column maintained at 35°C with eluent A (10 mM formic acid) 
and eluent B (acetonitrile), using a flow rate of 0.25 ml/min and a gradi-
ent of 8%–50% B over 4 minutes. SUA was detected using electrospray 
in negative mode with tandem mass spectrometry with a capillary volt-
age of 1.2 V at 194–150 (cone voltage 20 V) and internal standard at 
166.9–123 (cone voltage 20 V). Concentrations were calibrated against 
SUA [N-(2-hydroxybenzoyl)glycine, Apollo Scientific].
Tumor cell adhesion assay under flow. A flow-based adhesion assay 
coupled to live cell imaging was used, as described previously (82). 1.5 
× 104 LMVECs were seeded in μ-Slide IV0.4 (Ibidi) and grown to conflu-
ence. LMVECs, platelets, and tumor cells were pretreated with vehicle, 
aspirin (medium dose), SC-560, or NS-398 for 2 hours (LMVECs and 
B16F10 cells) or 30 minutes (platelets) and washed twice. 3 × 105 CMF-
DA-labeled B16F10 and 60 × 106 PKH26- labeled platelets (resuspend-
ed in PPP) were introduced to flow on an LMVEC monolayer at 0.05 
dyn/cm2 for 10 minutes, in the presence or absence of drugs. Shear 
stress was subsequently increased to 1 dyn/cm2 for 2 minutes to remove 
nonadhered cells or platelets. Image acquisition was performed using a 
Nikon Eclipse TE2000-E microscope (Nikon Plan Fluor 10×/0.30 Ph1 
DL objective) equipped with a Hamamatsu ORCA-ER digital camera 
(12 frames per minute). Shear-resistant adhesion and association with 
 platelets were quantified from 10 FOVs acquired before and after the 
increase of shear stress with Imaris software.
Immunofluorescence. Lungs were perfused with ice-cold PFA 
4% and stored in sucrose 25% (Sigma-Aldrich) at 4°C for 2 days. 
Eighteen- micrometer sections (cryostat microtome, Bright) from 
snap- frozen lungs were stained for E-selectin (MA1-06506, Thermo 
Fisher Scientific), VCAM-1 (CBL1300, Millipore), and vWF (ab11713, 
Abcam) using a TSA biotin amplification system (PerkinElmer).
Confocal microscopy. Z-stack images were acquired with an invert-
ed confocal microscope (LSM-710 and LSM-880, Zeiss) equipped 
with a Plan-Apochromat 20×/0.8 M27 objective. DAPI/CMAC 
(excitation, 405 nm; emission, 410–513 nm), GFP/Alexa Fluor 488/
CMFDA (excitation, 488 nm; emission, 490–653 nm), PE/CMRA 
(excitation, 543 nm; emission, 548–692 nm), PKH26 (excitation, 561 
nm; emission, 568–735 nm), and Alexa Fluor 633 (excitation, 633 nm; 
emission, 638–747 nm) were detected via a photomultiplier tube array 
(DAPI, CMAC, 4T1-GFP, Alexa Fluor 488, CMFDA, CMRA, PKH26, 
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